Clinical DataIN8bio announced 100% of leukemia patients (10/10) achieved durable complete remission (CR) at 1-year post stem cell transplant, beating standard of care RFS of 50-80%.
Financial PerformanceModel changes: increasing POS to 50% from 30% in AML, increasing PT to $6.50 from $5.00, reiterating BUY.
Market PotentialThe updated data continue to support the potential of the addition of INB-200 to standard of care to extend progression-free survival, which could also lead to improved overall survival.